Denali Capital Acquisition Corp Closes Business Combination with Semnur Pharmaceuticals

Winston & Strawn LLP represented Denali Capital Acquisition Corp. (OTCQB: DNQAF), a special purpose acquisition company, in the closing of its previously announced business combination with Semnur Pharmaceuticals, Inc., a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies and a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX). 

The combined company will operate under the name Semnur Pharmaceuticals, Inc., with its common stock and warrants expected to commence trading on the OTC Markets under the ticker symbols “SMNR” and “SMNRW”, respectively.